Wall Street Zen Upgrades bioAffinity Technologies (NASDAQ:BIAF) to “Hold”

bioAffinity Technologies (NASDAQ:BIAF) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of bioAffinity Technologies in a research note on Monday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

bioAffinity Technologies Stock Performance

Shares of NASDAQ:BIAF opened at $0.66 on Friday. The firm has a fifty day simple moving average of $1.14 and a two-hundred day simple moving average of $1.69. bioAffinity Technologies has a 52 week low of $0.61 and a 52 week high of $13.50. The company has a quick ratio of 1.34, a current ratio of 1.36 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $3.13 million, a P/E ratio of -0.06 and a beta of -1.11.

bioAffinity Technologies (NASDAQ:BIAF) last announced its earnings results on Friday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.40) by $1.59. The firm had revenue of $1.35 million for the quarter, compared to analysts’ expectations of $1.48 million. bioAffinity Technologies had a negative net margin of 280.53% and a negative return on equity of 285.75%.

Institutional Trading of bioAffinity Technologies

A number of large investors have recently made changes to their positions in BIAF. Geode Capital Management LLC acquired a new stake in bioAffinity Technologies in the fourth quarter valued at approximately $36,000. Scientech Research LLC acquired a new position in shares of bioAffinity Technologies during the third quarter worth $49,000. Finally, J. Safra Sarasin Holding AG purchased a new stake in shares of bioAffinity Technologies during the 1st quarter valued at $164,000. 1.64% of the stock is owned by hedge funds and other institutional investors.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.